PTPRC and leukemia: On day 60 (Figure S6C), all six control mice carried circulating human CD45-positive cells (mean ± SD, 81.8% ± 7.1%), while one mouse from each of the six treated with ABT-199 and the six treated with VXL was leukemia free.